P377 Safety profile and discontinuation rate of infliximab and adalimumab in patients with Crohn's disease and ulcerative colitis: experience from a tertiary care hospital in Qatar over a 7 year period
2013
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI